Gestational diabetes mellitus (GDM) is diagnosed in over 30,000 women a year in the UK. It commonly resolves after birth, but some 50% of women who have had GDM go on to develop type 2 diabetes,
The University of Birmingham, Dexter* and Cegedim Health Data have partnered in a trial of a new approach that automates finding and recruiting patients for randomised clinical trials (RCTs) and evaluates a specific intervention to improve the uptake of testing for type 2 diabetes amongst women at risk of the disease.
The RADIANT** trial is funded by the National Institute for Health and Care Research (NIHR) Research for Patient Benefit programme.
It will focus on gestational diabetes mellitus (GDM), which is diagnosed in over 30,000 women a year in the UK. Although GDM commonly resolves after giving birth, some 50% of women who have had GDM go on to develop type 2 diabetes, so all women diagnosed with it are advised to have yearly diabetes tests. However, few of them do.1
RADIANT will use Dexter’s new software platform, which was developed at the University’s Institute for Applied Health Research, to identify women who are suitable for inclusion in the trial from Cegedim Health Data’s real-world database, The Health Improvement Network (THIN), which is an anonymised database of primary care records.
Our aim in this trial is to validate that a data-driven approach offers better outcomes as well as time and cost savings. We are using just a small subset of the wealth of data that is captured in electronic patient records, and we hope that this first study is one of many more to come.
Dr Francesca Crowe, Institute of Applied Health Research, Univeristy of Birmingham
Cegedim will then use its own software to check eligibility, randomise women to the intervention or control group, and send a text message reminder to women in the intervention group. This will include a link to an animation developed at the University that details the purpose of the test, what it involves, and encourages them to book a diabetes test with their GP.
Dr Francesca Crowe, Lecturer in Epidemiology and Health Informatics, is leading the trial. She said: “Standard randomised controlled trials (RCTs) rely on manual methods to identify and include patients, which makes the process time-consuming and costly. Our aim in this trial is to validate that a data-driven approach offers better outcomes as well as time and cost savings, and we will also find out whether the text message and animation are acceptable and good value for money.”
As a long-standing partner of both the University of Birmingham and the NHS at large, we are delighted to be involved in their exemplar RADIANT study, which we also hope will mark a new era for data-driven, randomised controlled trials.
Samir Dhalla, Head of THIN, Cegedim Healthcare Solutions
Dr Crowe added: “We are using just a small subset of the wealth of data that is captured in electronic patient records, and we hope that this first study is one of many more to come.”
Participants in the RADIANT trial have been selected and NHS Ethics approval is in process to progress the active invention arm of the study.
* Dexter is an Operating Division managed by the University of Birmingham Enterprise Limited. Operating Divisions are an innovative model whereby University of Birmingham academics can set up their own commercial entity to operate in the commercial market, much like a limited company, but with the legal management, insurance and financial management being carried out by UoB Enterprise.
**RADIANT stands for impRoving testing for cardiometabolic diseases in those with previous gestational diabetes mellitus: an exemplar study on implementation and evaluation of a novel dAta-DrIven rANdomised clinical Trial platform in primary care
Leading the way in women's health research
Read more about our outstanding research in women's health.
For media information contact Ruth Ashton, University of Birmingham Enterprise, email: r.c.ashton@bham.ac.uk
About the University of Birmingham
The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 6,500 international students from over 150 countries.
University of Birmingham Enterprise helps students and researchers turn their ideas into new services, products and enterprises that meet real-world needs. We also support innovators and entrepreneurs with mentoring, advice, and training and manage the University’s Academic Consultancy Service. Follow us on LinkedIn and Twitter.
About Dexter
Dexter is a provider of a software platform created by researchers and clinicians at the University of Birmingham, UK. It encompasses many years of academic research into ‘knowledge engineering’ that enables automatic transformation of heterogeneous real-world data (RWD), such as from primary health care or insurance data into data usable for analyses and generation of actionable insights and results, or real-world evidence (RWE).
About Cegedim Health Data
Cegedim Health Data is the health data division of Cegedim Group, an innovative technology, services and real-world data group that has specialized in healthcare for more than 50 years. It covers seven European countries, providing anonymized Real-World Data and Evidence (RWD-E) platforms and advanced studies to drive research and cutting-edge improvements in patient outcomes in the interests of public health. Through THIN®️ (The Health Improvement Network), it offers immediate access to a data history of over 25 years and millions of anonymized patient records. Cegedim Health Data works with researchers, health authorities, pharma and medical device companies. It supports them across the pharma value chain, from R&D, market access and medical, to sales and marketing.
In France, the health data activity operates under the GERS Data brand. Follow us on Linkedin and Twitter.
For media information contact Lindsay Meredith Head of Marketing, mobile: +44 (0) 07850 341968.
About NIHR:
The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
Funding high quality, timely research that benefits the NHS, public health and social care;
Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.
NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.
Reference:
Screening for type 2 diabetes after a diagnosis of gestational diabetes by ethnicity: A retrospective cohort study, Primary Care Diabetes, Volume 16, Issue 3, June 2022, Pages 445-451. Available at doi: 10.1016/j.pcd.2022.03.008
